Expedited Loading with Intravenous Sotalol and Mobile ECG Monitoring – Primary Results of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry.

Steinberg BA, Deering TF, Holubkov R, et al. Expedited Loading with Intravenous Sotalol and Mobile ECG Monitoring – Primary Results of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry. Poster Presented at Heart Rhythm Society 2023; May 19 -21, 2023; New Orleans, LA.

In their poster presented at the Heart Rhythm Society 2023 meeting in New Orleans, Dr. Steinberg et al provided an overview of the results of the PEAKS Sotalol IV registry.  In that multicenter, prospective evaluation of 151 patients, which included pharmacokinetics / pharmacodynamics profiles and mobile ECG monitoring, the mean length of stay was 0.8 days. Sotalol IV was viewed as safe and feasible, with low rates of adverse events and shortened length of hospitalization.

Steinberg BA, Deering TF, Holubkov R, et al. Expedited Loading with Intravenous Sotalol and Mobile ECG Monitoring – Primary Results of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry. Poster Presented at Heart Rhythm Society 2023; May 19 -21, 2023; New Orleans, LA.
PEAKS poster (Steinberg et al) presented at HRS 2023.

Sotalol IV MAY CAUSE LIFE THREATENING PROARRYTHMIA and is associated with QT interval prolongation. Please see the full prescribing information including boxed warning, precautions, and contraindications at altathera.com/sotalol-iv-pi/.